Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity

Journal of Clinical Pharmacology

Volumn 42, Issue 6, 2002, Pages 613-619

  O'Neil, William M ^a   MacArthur, Rodger D ^a   Farrough, Marti J ^a   Doll, Mark A ^b   Fretland, Adrian J ^c   Hein, David W ^d   Crane, Lawrence R ^e   Svensson, Craig K ^e  

^a DIVISION OF REPRODUCTIVE BIOLOGY   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c RESEARCH AND DEVELOPMENT   (Australia)

^d College of Chemistry and Molecular Engineering ^*  (China)

^e WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ARYLAMINE ACETYLTRANSFERASE; COTRIMOXAZOLE; NAT2 PROTEIN, HUMAN; SULFONAMIDE;

ACETYLATION; ADULT; ARTICLE; DRUG HYPERSENSITIVITY; FEMALE; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METABOLISM; MIDDLE AGED; PHENOTYPE; ACETYLATOR PHENOTYPE; ANTIBIOTIC THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FEVER; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; RASH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ACETYLATION; ADULT; ANTI-INFECTIVE AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; DRUG HYPERSENSITIVITY; FEMALE; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; HUMAN; MIDDLE AGE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0036000311     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00970002042006004     Document Type: Article

References (29)

1. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia
2. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection
3. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men
4. Drug hypersensitivity reactions and human immunodeficiency virus disease
5. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: Clinical syndromes and pathogenesis
6. Acetylation phenotype and cutaneous hypersensitivity to trimethoprim-sulphamethoxazole in HIV-infected patients
7. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome
8. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions
9. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity
10. Acetylator status and tolerance of high-dose trimethoprim-sulfamethoxazole therapy among patients with human immunodeficiency virus
11. N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients
12. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes
13. Clinical pharmacokinetics of dapsone
14. Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele specific amplification
15. Pitfalls in N-acetyltransferase 2 genotyping
16. Adverse reactions to trimethoprim-sulfamethoxazole
17. N-acetyltransferase 2 polymorphism in patients infected with human immunodeficiency virus
18. The association of opportunistic infections with the occurrence of trimethoprim/sulfamethoxazole hypersensitivity in patients infected with human immunodeficiency virus
19. Acetylator phenotype and genotype in patients infected with HIV: Discordance between methods for phenotype determination and genotype
20. A simple test for acetylator phenotype using caffeine
21. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity
22. Prospective evaluation of detoxification pathways as markers of cutaneous adverse reactions to sulphonamides in AIDS
23. HIV-Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state
24. Glutathione deficiency and human immunodeficiency virus infection
25. Decreased release of glutathione into the systemic circulation of patients with HIV infection
26. Glutathione depletion in HIV-infected patients: Role of cysteine deficiency and effect of oral N-acetylcysteine
27. Intracellular glutathione levels in T cell subsets decrease in HIV-infected individuals
28. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals
29. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfonamide-induced cutaneous drug reactions